The Chinese biological drug Adalimumab injection has been approved for market.

On August 5th, the Adalimumab injection developed by China Biological Wuhan Institute of Biological Products received the "Drug Registration Certificate" issued by the National Medical Products Administration. This product is the first fully human monoclonal antibody drug independently developed and approved for production by a company in Hubei Province as the holder of the marketing authorization. The indications obtained are completely consistent with the 8 indications approved domestically for the original drug, which are used for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children, and Crohn's disease in children.